Key facts
- It has raised $420.0M across 1 recorded rounds; the latest was Later Stage VC (Series D) ($130.0M) in Feb 2026.
- Notable investors include Oriza Holdings, RA Capital Management, GL Ventures, Legend Capital, OrbiMed — 24 tracked in total.
- Status: Privately Held (backing).
Leadership
- Ann ZoveinChief Scientific Officer
- Lei ZhengChief Technology Officer
- Michael ArenbergChief Financial Officer
- ·Post-money valuations for all 1 rounds
- ·The complete investor list — 24 names
- ·Watchlist + deal alerts for Angitia Biopharmaceuticals
Funding rounds
1 roundsAbout Angitia Biopharmaceuticals
Operator of a global clinical-stage biotechnology company intended for the discovery and development of breakthrough therapies. The company focuses on the research and development of drugs for bone, muscle, and joint diseases, with innovative drugs, enabling patients to recover from severe musculoskeletal diseases.
- Industry
- Drug Discovery
- Sector
- Healthcare
- HQ
- Westlake Village, CA, United States
- Founded
- 2018
- Employees
- 51
- Website
- angitiabio.com/
- Ownership
- Privately Held (backing)
Angitia Biopharmaceuticals doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Angitia Biopharmaceuticals shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Angitia Biopharmaceuticals in its N-PORT filings yet. We sweep new filings monthly.